NCT03925051View on ClinicalTrials.gov

Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

March 21, 2020

Study Completion Date

June 18, 2020

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

Prolia®

mAb targeting RANKL. human monoclonal antibody targeting RANKL.

DRUG

CMAB807

human monoclonal antibody targeting RANKL.

Trial Locations (1)

200032

Zhongshan Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Biomabs Pharmaceutical Co., Ltd.

INDUSTRY

NCT03925051 - Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers | Biotech Hunter | Biotech Hunter